ANI Pharmaceuticals, Inc. (ANIP) Financial Ratios
28 years of historical data (1998–2025) · Healthcare · Drug Manufacturers - Specialty & Generic
EV/EBITDA
↓
9.01
↓-75% vs avg
5yr avg: 36.13
30Y Low8.5·High45.2
P/FCF
↓
9.63
↓-31% vs avg
5yr avg: 13.91
30Y Low9.0·High135.6
P/B Ratio
↑
3.30
↑+46% vs avg
5yr avg: 2.27
30Y Low0.9·High20.3
ROE
↑
16.2%
↓+752% vs avg
5yr avg: -2.5%
30Y Low-321%·High32%
Debt/EBITDA
↓
1.61
↓-87% vs avg
5yr avg: 12.74
30Y Low1.6·High38.5
Percentile shows where the current value sits in 30-year historical distribution. Sparklines show 5-year trend.
ANIP Valuation Multiples
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
ANI Pharmaceuticals, Inc. trades at 25.3x earnings, 39% below its 5-year average of 41.2x, sitting at the 38th percentile of its historical range. Compared to the Healthcare sector median P/E of 22.1x, the stock trades at a premium of 14%. On a free-cash-flow basis, the stock trades at 9.6x P/FCF, 31% below the 5-year average of 13.9x.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $1.8B | $1.7B | $1.1B | $1.0B | $654M | $580M | $347M | $743M | $530M | $744M | $702M |
| Enterprise Value | $1.8B | $1.7B | $1.5B | $1.1B | $892M | $767M | $525M | $866M | $670M | $915M | $795M |
| P/E Ratio → | 25.32 | 23.78 | — | 58.66 | — | — | — | 123.34 | 34.11 | — | 178.29 |
| P/S Ratio | 2.02 | 1.90 | 1.74 | 2.06 | 2.07 | 2.69 | 1.67 | 3.59 | 2.63 | 4.21 | 5.45 |
| P/B Ratio | 3.30 | 3.10 | 2.49 | 2.19 | 1.93 | 1.62 | 1.78 | 3.49 | 2.69 | 4.26 | 4.14 |
| P/FCF | 9.63 | 9.05 | 22.69 | 9.99 | — | — | — | 41.06 | 9.44 | — | — |
| P/OCF | 9.63 | 9.05 | 16.68 | 8.43 | — | 174.72 | 22.76 | 16.27 | 7.90 | 18.88 | 25.54 |
P/E links to full P/E history page with 30-year chart
ANIP EV Ratios
Enterprise-value multiples — capital-structure-neutral measures of total business value
ANI Pharmaceuticals, Inc.'s enterprise value stands at 9.0x EBITDA, 75% below its 5-year average of 36.1x. The Healthcare sector median is 14.1x, placing the stock at a 36% discount on an enterprise-value basis.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | 1.94 | 2.52 | 2.19 | 2.82 | 3.55 | 2.52 | 4.19 | 3.32 | 5.17 | 6.18 |
| EV / EBITDA | 9.01 | 8.47 | 22.65 | 10.00 | 36.62 | 102.89 | 18.35 | 14.20 | 9.70 | 16.26 | 18.74 |
| EV / EBIT | 16.42 | — | — | 22.81 | — | — | — | 53.71 | 19.25 | 31.29 | 23.40 |
| EV / FCF | — | 9.26 | 32.87 | 10.63 | — | — | — | 47.89 | 11.93 | — | — |
ANIP Profitability
Margins and return-on-capital ratios measuring operating efficiency
ANI Pharmaceuticals, Inc. earns an operating margin of 12.6%. Operating margins have expanded from 9.6% to 12.6% over the past 3 years, signaling improving operational efficiency. ROE of 16.2% indicates solid capital efficiency. ROIC of 11.2% represents solid returns on invested capital.
Margins
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | — | — | 59.3% | 62.7% | 56.1% | 53.5% | 58.2% | 69.4% | 63.8% | 55.3% | 62.1% |
| Operating Margin | 12.6% | 12.6% | 0.1% | 9.6% | -11.2% | -18.4% | -7.7% | 7.9% | 17.5% | 16.0% | 15.6% |
| Net Profit Margin | 8.9% | 8.9% | -3.0% | 3.9% | -15.1% | -19.7% | -10.8% | 3.0% | 7.7% | -0.6% | 3.1% |
Return on Capital
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | 16.2% | 16.2% | -4.2% | 4.7% | -13.7% | -15.4% | -11.0% | 3.0% | 8.3% | -0.6% | 2.4% |
| ROA | 5.8% | 5.8% | -1.7% | 2.3% | -6.3% | -6.9% | -4.9% | 1.4% | 3.7% | -0.3% | 1.3% |
| ROIC | 11.2% | 11.2% | 0.1% | 6.4% | -4.7% | -6.5% | -3.4% | 3.6% | 7.8% | 7.0% | 7.9% |
| ROCE | 9.9% | 9.9% | 0.1% | 6.6% | -5.2% | -7.5% | -4.1% | 5.0% | 11.1% | 8.5% | 7.1% |
ANIP Leverage & Debt
Solvency and debt-coverage ratios — lower is generally safer
ANI Pharmaceuticals, Inc. carries a Debt/EBITDA ratio of 1.6x, which is manageable (51% below the sector average of 3.3x). Net debt stands at $40M ($325M total debt minus $286M cash).
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.60 | 0.60 | 1.46 | 0.62 | 0.85 | 0.80 | 0.95 | 0.87 | 0.93 | 1.15 | 0.71 |
| Debt / EBITDA | 1.61 | 1.61 | 9.14 | 2.68 | 11.76 | 38.53 | 6.49 | 3.05 | 2.65 | 3.58 | 2.84 |
| Net Debt / Equity | — | 0.07 | 1.12 | 0.14 | 0.70 | 0.52 | 0.91 | 0.58 | 0.71 | 0.97 | 0.55 |
| Net Debt / EBITDA | 0.20 | 0.20 | 7.02 | 0.60 | 9.78 | 25.08 | 6.21 | 2.02 | 2.03 | 3.03 | 2.20 |
| Debt / FCF | — | 0.21 | 10.18 | 0.64 | — | — | — | 6.83 | 2.49 | — | — |
| Interest Coverage | — | — | 0.03 | 1.74 | -1.26 | -3.34 | -1.69 | 1.26 | 2.40 | 2.35 | 1.77 |
ANIP Liquidity & Efficiency
Short-term solvency ratios and asset-utilisation metrics
ANI Pharmaceuticals, Inc.'s current ratio of 2.71x is well above the 1.0 safety threshold, indicating strong short-term liquidity with ample room to cover current liabilities. The quick ratio of 2.19x is notably lower than the current ratio, indicating a significant portion of current assets is tied up in inventory. The current ratio has declined from 3.57x to 2.71x over the past 3 years.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 2.71 | 2.71 | 2.72 | 3.57 | 3.46 | 3.68 | 2.17 | 3.04 | 0.92 | 3.35 | 3.22 |
| Quick Ratio | 2.19 | 2.19 | 2.02 | 2.81 | 2.40 | 2.74 | 1.39 | 2.26 | 0.68 | 2.39 | 2.40 |
| Cash Ratio | 1.03 | 1.03 | 0.78 | 1.52 | 0.49 | 1.15 | 0.10 | 1.01 | 0.26 | 0.79 | 0.86 |
| Asset Turnover | — | 0.61 | 0.48 | 0.54 | 0.42 | 0.28 | 0.45 | 0.45 | 0.47 | 0.43 | 0.40 |
| Inventory Turnover | — | — | 1.83 | 1.63 | 1.32 | 1.23 | 1.43 | 1.31 | 1.80 | 2.09 | 1.86 |
| Days Sales Outstanding | — | 116.14 | 131.73 | 121.52 | 190.86 | 217.05 | 167.72 | 127.46 | 117.41 | 121.34 | 130.24 |
ANIP Shareholder Yields
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
ANI Pharmaceuticals, Inc. returns 0.7% to shareholders annually — split between a 0.1% dividend yield and 0.7% buyback yield. The earnings yield of 3.9% (inverse of P/E) provides a useful comparison to bond yields when assessing the stock's relative attractiveness to fixed income.
Dividends
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | 0.1% | 0.1% | 0.2% | 0.2% | 0.2% | 0.0% | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — | — | — | — | — |
Total Shareholder Return Metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | 3.9% | 4.2% | — | 1.7% | — | — | — | 0.8% | 2.9% | — | 0.6% |
| FCF Yield | 10.4% | 11.1% | 4.4% | 10.0% | — | — | — | 2.4% | 10.6% | — | — |
| Buyback Yield | 0.7% | 0.7% | 1.0% | 0.5% | 0.3% | 0.2% | 0.4% | 0.1% | 0.1% | 0.0% | 0.4% |
| Total Shareholder Yield | 0.7% | 0.8% | 1.2% | 0.7% | 0.5% | 0.2% | 0.4% | 0.1% | 0.1% | 0.0% | 0.4% |
| Shares Outstanding | — | $21M | $19M | $18M | $16M | $13M | $12M | $12M | $12M | $12M | $12M |
Peer Comparison
Compare ANIP with 10 similar companies in its peer group
| Company | Market Cap | P/E | EV/EBITDA | P/FCF | Gross Margin | Op Margin | ROE | ROIC | Debt/EBITDA |
|---|---|---|---|---|---|---|---|---|---|
 ANIPYou | $2B | 25.3 | 9.0 | 9.6 | — | 12.6% | 16.2% | 11.2% | 1.6 |
 AMRX | $4B | 61.9 | — | 15.9 | 36.9% | -0.2% | 15.7% | -0.2% | — |
 LNTH | $6B | 25.3 | 13.8 | 15.8 | 61.1% | 20.2% | 21.4% | 30.6% | 0.0 |
 PRGO | $2B | -1.2 | 7.5 | 11.6 | 35.1% | 8.1% | -39.3% | 3.7% | 5.8 |
 PAHC | $2B | 49.3 | 19.7 | 56.8 | 30.9% | 8.5% | 17.8% | 9.8% | 4.9 |
 SUPN | $3B | -75.7 | 52.6 | 64.4 | 89.6% | -5.1% | -3.7% | -2.8% | 0.7 |
 HI | $2B | 52.4 | 12.5 | 126.3 | 33.7% | 5.9% | 3.0% | 3.8% | 5.4 |
 SLDB | $561M | -3.6 | — | — | — | — | -109.9% | -120.8% | — |
 VTRS | $18B | -5.3 | — | 9.5 | 35.1% | -18.6% | -21.1% | -6.7% | — |
 MCK | $91B | 28.9 | 18.5 | 17.4 | 3.5% | 1.2% | — | 540.6% | 1.5 |
 CAH | $45B | 29.7 | 16.5 | 24.4 | 3.7% | 1.0% | — | 3378.7% | 3.0 |
| Healthcare Median | — | 22.1 | 14.1 | 18.7 | 63.9% | -5.3% | -33.7% | -10.8% | 3.3 |
Peer selection based on competitive and market overlap. Compare multiple stocks →
Download Financial Ratios Data
Includes 30+ ratios · 28 years · Updated daily
See ANIP's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs ANIP Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare ANIP vs AMRX
Side-by-side business, growth, and profitability comparison vs Amneal Pharmaceuticals, Inc..
Start ComparisonANIP — Frequently Asked Questions
Quick answers to the most common questions about buying ANIP stock.
What is ANI Pharmaceuticals, Inc.'s P/E ratio?
ANI Pharmaceuticals, Inc.'s current P/E ratio is 25.3x. The historical average is 61.9x. This places it at the 38th percentile of its historical range.
What is ANI Pharmaceuticals, Inc.'s EV/EBITDA?
ANI Pharmaceuticals, Inc.'s current EV/EBITDA is 9.0x. This enterprise value multiple compares the company's total value (equity + debt - cash) to its EBITDA. The historical average is 19.3x.
What is ANI Pharmaceuticals, Inc.'s ROE?
ANI Pharmaceuticals, Inc.'s return on equity (ROE) is 16.2%. The historical average is -56.3%.
Is ANIP stock overvalued?
Based on historical data, ANI Pharmaceuticals, Inc. is trading at a P/E of 25.3x. This is at the 38th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.
What is ANI Pharmaceuticals, Inc.'s dividend yield?
ANI Pharmaceuticals, Inc.'s current dividend yield is 0.06%.
What are ANI Pharmaceuticals, Inc.'s profit margins?
ANI Pharmaceuticals, Inc. has 12.6% operating margin. Operating margin between 10-20% is typical for established companies.
How much debt does ANI Pharmaceuticals, Inc. have?
ANI Pharmaceuticals, Inc.'s Debt/EBITDA ratio is 1.6x, indicating moderate leverage. A ratio below 2x is generally considered financially healthy.